scholarly journals Value of NSE and S100 Protein of Kawasaki Disease with aseptic meningitis in Infant

2019 ◽  
Vol 14 (1) ◽  
pp. 358-362
Author(s):  
Jiangtao Wang ◽  
Shouhang Chen ◽  
Xiaoling Wang ◽  
Huiru Gu ◽  
Junli Liu ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Kawasaki Disease ◽  
Aseptic Meningitis ◽  
Neuronal Damage ◽  
S100 Protein ◽  
Neuron Specific Enolase ◽  
Area Under The Curve ◽  
Control Group ◽  
Purulent Meningitis ◽  
And Control

AbstractThe cerebrospinal fluid content was examined for concentrations of S100 protein and neuron-specific enolase (NSE) in two diseases, Kawasaki disease (KD) with aseptic meningitis (1-3 months) and purulent meningitis (PM), to determine whether or not these measuremets could be used in early diagnosis. The content of cerebrospinal fluid S100 protein of KD with aseptic meningitis and PM were significantly higher than those in the control group. There was also a difference between KD and purulent meningitis (PM). The concentration of NSE was highest in the encephalitis group, which was statistically different from control group. However, there was no difference between the KD and control groups. The levels of S100 protein and NSE of KD with aseptic meningitis were lower than those in PM, indicating that the extent of neuronal damage is significantly lower than of the enchephalitis group. The area under the curve (AUCs) of the receiver operating characteristic (ROC) curve for S100 and NSE were both 0.972. The S100 threshold was 0.4315, the sensitivity was 92.1%, and the specificity was 100%, while the NSE threshold was 9.325, sensitivity 92.1%, and specificity 90%. The combined detection of NSE and S100 levels in the cerebrospinal fluid can be used for the differential diagnosis of KD with aseptic meningitis and purulent meningitis.

Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion

2020 ◽  
Vol 23 ◽  
Author(s):  
Erbu Yarci ◽  
Cuneyt Tayman ◽  
Ufuk Cakir ◽  
Utku Serkant
Keyword(s):  
Exchange Transfusion ◽  
Neuronal Damage ◽  
Neuron Specific Enolase ◽  
Endothelial Damage ◽  
Control Group ◽  
Control Groups ◽  
Term Neonates ◽  
Blood Exchange ◽  
Blood Exchange Transfusion ◽  
And Control

Background:: Hyperviscosity of blood secondary to polycythemia results in increased resistance to blood flow and decrease in delivery of oxygen. Objective:: To evaluate whether serum endocan, NSE and IMA levels can be compared in terms of endothelial injury/ dysfunction and neuronal damage in term neonates with polycythemia who underwent PET. Methods:: 38 symptomatic polycythemic newborns having PET and 38 healthy newborns were included in the study. Blood samples for endocan, NSE and IMA were taken at only postnatal 24 hours of age in the control group and in polycytemia group just before PET, at 24 and 72 hours after PET. Results:: The polycythemia group had higher serum endocan(1073,4 ± 644,8 vs. 378,8 ± 95,9ng/ml; p<0.05), IMA(1,32 ± 0,34 vs.0,601 ± 0,095absorbance unit; p<0.05) and NSE(44,7 ± 4,3 vs. 26,91 ± 7,12μg/l; p<0.05) levels than control group before the PET procedure. At 24 hours after PET, IMA(0,656 ± 0,07 vs. 0,601 ± 0,095absorbance unit; p<0.05) and endocan(510,9 ± 228,6 vs. 378,8 ± 95,9ng/ml; p<0.05) levels were closer to the control group, being still statistically significant higher. NSE levels decreased to control group levels having no difference between the PET and control groups at 24 hours after PET (28,98 ± 6,5 vs. 26,91 ± 7,12μg/l; p>0.05). At 72 hours after PET the polycythemia and control groups did not differ statistically for IMA, endocan and NSE levels (p>0.05). Conclusion:: Serum endocan and IMA levels can be used as a biomarker for endothelial damage / dysfunction and tissue hypoxia in infants with symptomatic polycytemia.

scholarly journals Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Akihiro Tsukahara ◽  
Takafumi Hosokawa ◽  
Daisuke Nishioka ◽  
Takuya Kotani ◽  
Shimon Ishida ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cervical Spondylotic Myelopathy ◽  
Characteristic Curve ◽  
Neuron Specific Enolase ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Control Group ◽  
Chemiluminescent Immunoassay ◽  
And Control ◽  
Lateral Sclerosis

AbstractThe current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with ALS, 23 with CSM, 28 controls, and 10 with Parkinson’s disease (PD) who underwent analysis of CSF NSE levels. The control group comprised patients aged above 45 years who underwent lumbar puncture because of suspected neurological disorders that were ruled out after extensive investigations. CSF NSE levels were evaluated using the electro-chemiluminescent immunoassay. The ALS group had significantly higher CSF NSE levels than the CSM and control groups (P < 0.001 for both comparisons). The CSM, control, and PD groups did not significantly differ in terms of CSF NSE levels. A receiver-operating characteristic curve analysis was performed to assess the diagnostic value of CSF NSE levels in distinguishing ALS from CSM. The area under the curve for CSF NSE levels was 0.86. The optimal cutoff value was 17.7 ng/mL, with a specificity of 87% and a sensitivity of 80%. Hence, CSF NSE levels are elevated in ALS and are effective in distinguishing ALS from CSM.

scholarly journals Elevated CSF Neuron-specific Enolase Levels in Amyotrophic Lateral Sclerosis (Als): A Useful Biomarker for Distinguishing ALS From Cervical Spondylotic Myelopathy

2021 ◽  
Author(s):  
Akihiro Tsukahara ◽  
Takafumi Hosokawa ◽  
Daisuke Nishioka ◽  
Takuya Kotani ◽  
Shimon Ishida ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cervical Spondylotic Myelopathy ◽  
Characteristic Curve ◽  
Neuron Specific Enolase ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Control Group ◽  
Control Groups ◽  
And Control ◽  
Lateral Sclerosis

Abstract The current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with ALS, 23 with CSM, and 28 controls who underwent analysis of CSF NSE levels. The control group comprised patients aged above 45 years who underwent lumbar puncture because of suspected neurological disorders that were ruled out after extensive investigations. CSF NSE levels were evaluated using the electro-chemiluminescent immunoassay. The ALS group had significantly higher CSF NSE levels than the CSM and control groups (P < 0.001 for both comparisons). The CSM and control groups did not significantly differ in terms of CSF NSE levels. A receiver-operating characteristic curve analysis was performed to assess the diagnostic value of CSF NSE levels in distinguishing ALS from CSM. The area under the curve for CSF NSE levels was 0.86. The optimal cutoff value was 17.7 ng/mL, with a specificity of 87% and a sensitivity of 80%. Hence, CSF NSE levels are elevated in ALS and are effective in distinguishing ALS from CSM.

Predictive value of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-neutrophil ratio, and neutrophil-to-monocyte ratio in lupus nephritis

Lupus ◽  
2020 ◽  
Vol 29 (9) ◽  
pp. 1031-1039
Author(s):  
Peng Liu ◽  
Peiyuan Li ◽  
Zhong Peng ◽  
Yazhou Xiang ◽  
Chenqi Xia ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Healthy Subjects ◽  
Area Under The Curve ◽  
Neutrophil To Lymphocyte Ratio ◽  
Control Group ◽  
Receiver Operating Characteristic Curves ◽  
Lymphocyte Ratio ◽  
And Control ◽  
First Time

Objective To evaluate the role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-neutrophil ratio (PNR), platelet-to-monocyte ratio (PMR), and neutrophil-to-monocyte ratio (NMR) as predictors for lupus nephritis (LN) patients without infection or as biomarkers for distinguishing between infection or flare with LN patients. Methods LN patients were divided into three groups: LN without infection, LN with infection, and LN with flare. A total of 57 healthy subjects were enrolled as controls. The differentiation was analyzed between LN without infection and control group, and LN with infection and LN with flare. Correlations among variables were assessed in the LN group without infection. Receiver operating characteristic curves were constructed in two comparable groups. Results NLR, PLR, and MLR were increased significantly in the LN group without infection as compared with those in healthy controls. NLR (area under the curve (AUC): 0.75) and MLR (AUC: 0.79) were useful for distinguishing between LN patients without infection and healthy subjects. In differentiating LN patients without infection from the controls, optimal cutoffs of NLR and MLR were 3.43 (sensitivity: 45.6%, specificity: 96.5%, and overall accuracy: 68.8%) and 0.24 (sensitivity: 75.0%, specificity: 73.7%, and overall accuracy: 73.6%), respectively. In addition, NLR ( r = 0.322, p = 0.011) and PLR ( r = 0.283, p = 0.026) were positively correlated with CRP. Importantly, NLR and NMR were increased while PNR was decreased in the LN group with infection in comparison with those in the LN group with flare. NLR (AUC: 0.80), NMR (AUC: 0.78), and PNR (AUC: 0.74) were useful in differentiating LN patients with infection and flare, and their optimal cutoffs were 4.02 (sensitivity: 82.6%, specificity: 69.6%, and overall accuracy: 75.5%), 12.19 (sensitivity: 80.4%, specificity: 73.9%, and overall accuracy: 77.5%), and 28.26 (sensitivity: 65.2%, specificity: 76.8%, and overall accuracy: 71.6%), respectively. Conclusions We demonstrated, for the first time, that MLR or NMR had the best accuracy in differentiating LN patients without infection from healthy subjects, or differentiating infection from flare in LN patients, respectively. Our results implied that NLR, MLR, PNR, and NMR may be useful biomarkers in predicting LN.

Prediction of regaining consciousness despite an early epileptiform EEG after cardiac arrest

Neurology ◽  
2020 ◽  
Vol 94 (16) ◽  
pp. e1675-e1683 ◽  
Author(s):  
Giuseppina Barbella ◽  
Jong Woo Lee ◽  
Vincent Alvarez ◽  
Jan Novy ◽  
Mauro Oddo ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Operating Characteristic ◽  
Neuronal Damage ◽  
Cerebral Performance Category ◽  
Neuron Specific Enolase ◽  
Area Under The Curve ◽  
Performance Category ◽  
Receiver Operating Characteristic Curves ◽  
Normal Background ◽  
Serum Neuron Specific Enolase

ObjectiveAfter cardiac arrest (CA), epileptiform EEG, occurring in about 1/3 of patients, often but not invariably heralds poor prognosis. We tested the hypothesis that a combination of specific EEG features identifies patients who may regain consciousness despite early epileptiform patterns.MethodsWe retrospectively analyzed a registry of comatose patients post-CA (2 Swiss centers), including those with epileptiform EEG. Background and epileptiform features in EEGs 12–36 hours or 36–72 hours from CA were scored according to the American Clinical Neurophysiology Society nomenclature. Best Cerebral Performance Category (CPC) score within 3 months (CPC 1–3 vs 4–5) was the primary outcome. Significant EEG variables were combined in a score assessed with receiver operating characteristic curves, and independently validated in a US cohort; its correlation with serum neuron-specific enolase (NSE) was also tested.ResultsOf 488 patients, 107 (21.9%) had epileptiform EEG <72 hours; 18 (17%) reached CPC 1–3. EEG 12–36 hours background continuity ≥50%, absence of epileptiform abnormalities (p < 0.00001 each), 12–36 and 36–72 hours reactivity (p < 0.0001 each), 36–72 hours normal background amplitude (p = 0.0004), and stimulus-induced discharges (p = 0.0001) correlated with favorable outcome. The combined 6-point score cutoff ≥2 was 100% sensitive (95% confidence interval [CI], 78%–100%) and 70% specific (95% CI, 59%–80%) for CPC 1–3 (area under the curve [AUC], 0.98; 95% CI, 0.94–1.00). Increasing score correlated with NSE (ρ = −0.46, p = 0.0001). In the validation cohort (41 patients), the score was 100% sensitive (95% CI, 60%–100%) and 88% specific (95% CI, 73%–97%) for CPC 1–3 (AUC, 0.96; 95% CI, 0.91–1.00).ConclusionPrognostic value of early epileptiform EEG after CA can be estimated combining timing, continuity, reactivity, and amplitude features in a score that correlates with neuronal damage.

Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis

2008 ◽  
Vol 14 (4) ◽  
pp. 557-560 ◽  
Author(s):  
M Kawajiri ◽  
M Mogi ◽  
M Osoegawa ◽  
T Matsuoka ◽  
K Tsukuda ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Angiotensin Ii ◽  
Neurological Diseases ◽  
Control Group ◽  
Autoimmune Encephalomyelitis ◽  
Disability Status ◽  
Scale Scores ◽  
Inflammatory Neuropathies ◽  
And Control

We previously demonstrated that angiotensin II acts as a crucial neuroprotective factor after neural injury through angiotensin II type-2 (AT2) receptor signaling. Although the pathway is known to play an important role in the development of experimental autoimmune encephalomyelitis, cerebrospinal fluid (CSF) angiotensin II levels in patients with multiple sclerosis (MS) have never been studied. To clarify the significance of angiotensin II in MS, we assayed angiotensin II concentrations using an established enzyme-linked immunoabsorbent assay in CSF samples from patients with MS ( n = 21), patients with inflammatory neuropathies (IN) ( n = 23) and control individuals who did not have either of the neurological diseases or any other disease that might affect the angiotensin II levels in the CSF (control) ( n = 24). Angiotensin II levels in the CSF were 3.79 ± 1.54 pg/ml in the MS group, 5.13 ± 2.27 pg/ml in the IN group and 6.71 ± 2.65 pg/ml in the control group. The angiotensin II levels in the CSF of the MS group were significantly lower than in the control group ( p = 0.00057). Angiotensin II concentration in the CSF tended to have a negative correlation with the Kurtzke’s Expanded Disability Status Scale scores during MS relapse ( p = 0.0847). These findings suggest that reduced levels of intrathecal angiotensin II may be related to the abnormal neural damage and repair processes in MS.

Accuracy of cerebrospinal fluid ferritin for purulent meningitis

2020 ◽  
pp. archdischild-2019-317960
Author(s):  
Pedro Celiny Ramos Garcia ◽  
Andrea Lucia Machado Barcelos ◽  
Cristian Tedesco Tonial ◽  
Humberto Holmer Fiori ◽  
Paulo Roberto Einloft ◽  
...  
Keyword(s):  
Emergency Department ◽  
Cerebrospinal Fluid ◽  
Aseptic Meningitis ◽  
Clinical Symptoms ◽  
Clinical Suspicion ◽  
Purulent Meningitis

ObjectiveTo evaluate the use of cerebrospinal fluid (CSF) ferritin levels in the diagnosis of purulent meningitis (PM).MethodWe studied 81 children between 28 days and 12 years of age who presented with clinical suspicion of meningitis to the emergency department. CSF ferritin levels were measured and compared between diagnostic groups (PM, aseptic meningitis (AM) and no meningitis).ResultsThe median age was 24 (IQR 8–69) months. There were 32 patients with AM (39%), 23 with PM (28%) and 26 with no meningitis (32%). Median CSF ferritin was 4.2 ng/mL (IQR 3.0–6.5), 52.9 ng/mL (IQR 30.7–103 ng/mL) and 2.4 ng/mL (IQR 2–4), respectively. CSF ferritin was higher in children with PM compared with AM (p<0.001) or no meningitis (p<0.001). There was no difference between AM and no meningitis.ConclusionCSF ferritin may be a useful biomarker to discriminate PM in children with clinical symptoms of this disease.

Cerebrospinal Fluid and Serum Neuron-Specific Enolase in Acute Benign Headache

Cephalalgia ◽  
2008 ◽  
Vol 28 (5) ◽  
pp. 506-509 ◽  
Author(s):  
M Casmiro ◽  
E Scarpa ◽  
P Cortelli ◽  
L Vignatelli
Keyword(s):  
Cerebrospinal Fluid ◽  
Neuronal Damage ◽  
Hypertensive Crisis ◽  
Neuron Specific Enolase ◽  
Hypertensive Encephalopathy ◽  
Tension Type Headache ◽  
Type Headache ◽  
Head Computed Tomography ◽  
Serum Ratio ◽  
Serum Neuron Specific Enolase

We determined the cerebrospinal fluid (CSF) and serum neuron-specific enolase (NSE) concentrations in 19 patients with acute benign headache. All patients had normal neurological examination, CSF and head computed tomography scan. The final diagnoses were: primary thunderclap headache ( n = 7), primary exertional headache ( n = 3), primary cough headache ( n = 1), migraine without aura ( n = 4), headache unspecified ( n = 2), probable infrequent episodic tension-type headache ( n = 1), headache attributed to hypertensive crisis without hypertensive encephalopathy ( n = 1). A group of 108 healthy subjects served as controls. CSF NSE concentration was 14.16 ng/ml [95% confidence interval (CI) 11.86, 16.47)] in the headache sample (controls 17.19 ng/ml, 95% CI 16.23, 18.15). Serum NSE concentration was 7.50 ng/ml (95% CI 5.20, 9.80) in the headache sample (controls 8.45 ng/ml, 95% CI 7.67, 9.23). CSF/serum ratio was 2.81 (95% CI 2.21, 3.40) in the headache sample (controls 2.23, 95% CI 2.03, 2.42). Acute benign headache is not associated with neuronal damage as estimated by means of CSF and serum NSE concentration.

scholarly journals Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: A preliminary report

2008 ◽  
Vol 31 (6) ◽  
pp. 351 ◽  
Author(s):  
Heng-qiang Gao ◽  
Hai-yan Zhu ◽  
Yan-qiang Zhang ◽  
Le-xin Wang
Keyword(s):  
Cerebrospinal Fluid ◽  
Preliminary Report ◽  
Control Group ◽  
Post Stroke ◽  
Depressed Patients ◽  
Post Stroke Depression ◽  
Serotonin Deficiency ◽  
And Control ◽  
Plasma Serotonin

Objective: To investigate the plasma and cerebrospinal fluid (CSF) concentrations of serotonin in patients with post-stroke depression (PSD). Methods: Serotonin was measured in 30 PSD patients and 30 controls on day 15 and day 30 following stroke. Result: There was a good correlation between the plasma and the CSF serotonin concentrations in both PSD (r = 0.641, P = 0.001) and control patients (0.852, P = 0.001) 30 days following the stroke. The average plasma and CSF serotonin concentrations in the PSD patients were lower than in the control group on day 15 (CSF: 0.24±0.27 vs 0.82±0.48 µmol/L, P < 0.01; plasma, 0.32±0.25 vs 0.83±0.45µmol/L, P < 0.01) and day 30 (CSF: 0.29±0.23 vs 0.78±0.47 µmol/L, P < 0.01; plasma, 0.31±0.33 vs 0.89±0.67 µmol/L, P < 0.01). Reduction of plasma serotonin was found in 90.0% of the PSD group and 13.3% of the control group patients (P < 0.01). Reduction in CSF serotonin in the PSD and control group was 80.0% and 6.7% respectively (P < 0.01%). Conclusion: Plasma serotonin levels may be used to represent the CSF serotonin levels in depressed and non-depressed patients following stroke. There is a reduction in the plasma or CSF serotonin concentrations in patients with PSD. Serotonin deficiency may be one of the factors leading to depression following stroke.

Sign in / Sign up

Export Citation Format

Share Document